Literature DB >> 26738429

New concepts on BARD1: Regulator of BRCA pathways and beyond.

Irmgard Irminger-Finger1, Magda Ratajska2, Maxim Pilyugin3.   

Abstract

For nearly two decades most research on BARD1 was closely linked to research on BRCA1, the breast cancer predisposition gene. The co-expression of BARD1 and BRCA1 genes in most tissues, the nearly identical phenotype of Bard1 and Brca1 knock-out mice, and the fact that BRCA1 and BARD1 proteins form a stable complex, led to the general assumption that BARD1 acts as an accessory to BRCA1. More recent research on both proteins showed that BRCA1 and BARD1 might have common as well as separate functions. This review is an overview of how BARD1 functions and controls BRCA1. It highlights also experimental evidence for dominant negative, tumor promoting, functions of aberrant isoforms of BARD1 that are associated with and drivers of various types of cancer.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Alternative splicing; Cancer biomarker; Cancer predisposition; Cancer treatment; Competing endogenous RNA

Mesh:

Substances:

Year:  2015        PMID: 26738429     DOI: 10.1016/j.biocel.2015.12.008

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  31 in total

1.  BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites.

Authors:  Zhaohua Hu; Shaojie Mi; Ting Zhao; Changmin Peng; Yihan Peng; Lulu Chen; Wenge Zhu; Yi Yao; Qibin Song; Xiangpan Li; Xinzhi Li; Chenxi Jia; Huadong Pei
Journal:  EMBO J       Date:  2020-04-29       Impact factor: 11.598

Review 2.  The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.

Authors:  Weixing Zhao; Claudia Wiese; Youngho Kwon; Robert Hromas; Patrick Sung
Journal:  Annu Rev Biochem       Date:  2019-03-27       Impact factor: 23.643

Review 3.  Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment.

Authors:  Shuang Li; Jing Zhao; Dong Shang; Daniel J Kass; Yutong Zhao
Journal:  JCI Insight       Date:  2018-05-17

4.  Differential Expression of BARD1 Isoforms in Melanoma.

Authors:  Lorissa I McDougall; Ryan M Powell; Magdalena Ratajska; Chi F Lynch-Sutherland; Sultana Mehbuba Hossain; George A R Wiggins; Agnieszka Harazin-Lechowska; Bożena Cybulska-Stopa; Jyoti Motwani; Erin C Macaulay; Glen Reid; Logan C Walker; Janusz Ryś; Michael R Eccles
Journal:  Genes (Basel)       Date:  2021-02-23       Impact factor: 4.096

5.  BARD1 nonsense variant c.1921C>T in a patient with recurrent breast cancer.

Authors:  Jennifer Gass; Madeline Tatro; Patrick Blackburn; Stephanie Hines; Paldeep S Atwal
Journal:  Clin Case Rep       Date:  2017-01-04

Review 6.  Dualistic Role of BARD1 in Cancer.

Authors:  Flora Cimmino; Daniela Formicola; Mario Capasso
Journal:  Genes (Basel)       Date:  2017-12-08       Impact factor: 4.096

7.  BARD1 serum autoantibodies for the detection of lung cancer.

Authors:  Maxim Pilyugin; Pascaline Descloux; Pierre-Alain André; Viktoria Laszlo; Balazs Dome; Balazs Hegedus; Sylvain Sardy; Samuel Janes; Andrea Bianco; Geoffrey J Laurent; Irmgard Irminger-Finger
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

8.  BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility.

Authors:  Wen Fu; Jinhong Zhu; Si-Wei Xiong; Wei Jia; Zhang Zhao; Shi-Bo Zhu; Jin-Hua Hu; Feng-Hua Wang; Huimin Xia; Jing He; Guo-Chang Liu
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

9.  Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.

Authors:  Maxim Pilyugin; Pierre-Alain André; Magdalena Ratajska; Alina Kuzniacka; Janusz Limon; Benjamin B Tournier; Julien Colas; Geoff Laurent; Irmgard Irminger-Finger
Journal:  Oncotarget       Date:  2017-02-07

Review 10.  Drugging the Cancers Addicted to DNA Repair.

Authors:  Jac A Nickoloff; Dennie Jones; Suk-Hee Lee; Elizabeth A Williamson; Robert Hromas
Journal:  J Natl Cancer Inst       Date:  2017-11-01       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.